Freestone Grove Partners LP Takes $15.48 Million Position in Edwards Lifesciences Corporation $EW

Freestone Grove Partners LP purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, HoldingsChannel reports. The fund purchased 171,081 shares of the medical research company’s stock, valued at approximately $15,476,000.

A number of other large investors have also recently bought and sold shares of the stock. Caisse de depot et placement du Quebec acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $87,523,000. Man Group plc acquired a new stake in Edwards Lifesciences during the 2nd quarter worth $84,597,000. Jupiter Topco LLC bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth $112,188,000. EFG International AG bought a new position in Edwards Lifesciences during the second quarter worth about $91,000. Finally, Primecap Management Co. CA bought a new position in Edwards Lifesciences during the second quarter worth about $308,314,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,857 shares of company stock worth $170,305 over the last three months. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of EW opened at $89.97 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market capitalization of $51.81 billion, a PE ratio of 51.71, a PEG ratio of 2.38 and a beta of 0.85. The company’s 50-day moving average is $89.48 and its 200-day moving average is $84.99. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Evercore reissued an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Truist Financial upped their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.